Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis.

Autor: Wiegel J; Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Admiraal Helfrichstraat 1, 1056 AA, Amsterdam, The Netherlands. j.wiegel@reade.nl.; Rheumatology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. j.wiegel@reade.nl.; Amsterdam Infection and Immunity, Amsterdam, The Netherlands. j.wiegel@reade.nl., Seppen BF; Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Admiraal Helfrichstraat 1, 1056 AA, Amsterdam, The Netherlands.; Rheumatology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Amsterdam Infection and Immunity, Amsterdam, The Netherlands., Nurmohamed MT; Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Admiraal Helfrichstraat 1, 1056 AA, Amsterdam, The Netherlands.; Rheumatology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Amsterdam Infection and Immunity, Amsterdam, The Netherlands., Bos WH; Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Admiraal Helfrichstraat 1, 1056 AA, Amsterdam, The Netherlands., Ter Wee MM; Epidemiology and Data Science, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Societal Participation and Health, Amsterdam Public Health, Amsterdam, The Netherlands.; Amsterdam Public Health, Methodology, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: BMC rheumatology [BMC Rheumatol] 2022 Nov 30; Vol. 6 (1), pp. 73. Date of Electronic Publication: 2022 Nov 30.
DOI: 10.1186/s41927-022-00303-w
Abstrakt: Background: The use of frequent electronic patient reported outcome measures (ePRO's) enables monitoring disease activity at a distance (telemonitoring) in patients with inflammatory arthritis. However, telemonitoring studies report declining long-term adherence to reporting ePRO's, which may oppose the benefits of telemonitoring. Therefore, the objective was to investigate what factors are associated with (non-)adherence to telemonitoring with a weekly ePRO in patients with inflammatory arthritis (IA).
Methods: We performed a prospective cohort study in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at Reade Amsterdam, The Netherlands. Patients telemonitored their disease activity weekly for 6 months with a modified Multidimensional Health Assessment Questionnaire completed in a smartphone application. The primary outcome was time to dropout, defined as ≥ 4 weeks of consecutively nonresponse. Based on literature and through expert meetings, a predefined set of 13 baseline factors were selected to assess the association with time to dropout through a multivariable Cox-regression analysis.
Results: A total of 220 consecutive patients were included (mean age 54, SD 12; 55% females; 99 RA, 81 PsA, and 40 AS). A total of 141 patients (64%) dropped out, with a median time to dropout of 17 weeks (IQR 9-26). Women had a significant higher chance to dropout over 6 months compared to men (HR 1.58, 95% CI 1.06-2.36).
Conclusion: In the set of investigated factors, women stopped reporting the weekly ePRO sooner than men. Future focus group discussions will be performed to investigate the reasons for dropout, and in specific why women dropped out sooner. Trial registration This trials was prospectively registered at www.trialregister.nl (NL8414).
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: